-
Long-term Extension Study Of Ulviprubart (ABC008) In Subjects With Inclusion Body Myositis
Jacksonville, FL; Rochester, MN
ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and:
* Have completed the Part 2 (Multiple Ascending Dose \[MAD\]) End of-Treatment (EOT) Visit in Study ABC008-IBM-101; subjects who continued further on into Part 3 of the study (MAD Extension) prior to enrolling in this study are also eligible; OR
* Have completed the Week 80 Follow-up Visit in Study ABC008-IBM-201.
-
A Study To Determine The Efficacy And Safety Of ABC008 For Inclusion Body Myositis
Jacksonville, FL; Rochester, MN
The purpose of this study is to determine the effectiveness, safety, and tolerability of subcutaneous (SC) dosing of ABC008 in subjects with inclusion body myositis (IBM).
-
Gene Analysis in Families with Probable Inclusion Body Myositis with or without and ALS
Rochester, MN
This study proposes to identify the molecular defect in families with a clinical phenotype of “probable Inclusion Body Myositis” (“probable IBM”) but affecting more than one family members, with or without family history of ALS.